查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049453

α1-抗胰蛋白酶缺乏症治療市場報告：按治療方法、給藥途徑、最終用戶和地區分類（2026-2034 年）

Alpha 1 Antitrypsin Deficiency Treatment Market Report by Treatment Type, Route of Administration, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球α-1抗胰蛋白酶缺乏症治療市場規模達23億美元。展望未來，IMARC Group預測，到2034年，市場規模將達到44億美元，2026年至2034年的複合年成長率為7.14%。

α1-抗胰蛋白酶（AAT）缺乏症是一種遺傳性疾病，患者體內無法產生足夠的AAT蛋白。 AAT蛋白對於保護肺部和肝臟免受體內其他蛋白質的不良影響至關重要。嚴重的AAT缺乏症患者可能會發展為肝硬化、慢性阻塞性肺病（COPD）和肺氣腫。此疾病可透過基因檢測或血液檢查進行診斷。治療方法包括增強療法、肺部復健和氧氣療法，並可使用支氣管擴張劑和皮質類固醇等藥物進行靜脈或吸入治療。

呼吸系統疾病的日益普遍是市場成長的主要促進因素之一。此外，增強療法的普及也促進了市場成長。此療法可從健康捐贈者的血漿中提取α1-抗胰蛋白酶（AAT）蛋白，以提高患者氣道內AAT的濃度。因此，由於該治療方法能夠延緩肺氣腫的進展、減少病情加重的頻率並提高康復率，因此越來越受到患者和醫療專業人員的支持。此外，診斷技術的進步以及AAT生產和純化創新製程的開發也推動了市場成長。這些產品品質得到提升，且不含病毒和細菌等污染物。其他因素，例如廣泛的研發活動和醫療基礎設施的改善，預計也將進一步推動市場發展。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：α1-抗胰蛋白酶缺乏症治療的全球市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依治療方法分類

  • 替代療法
  • 支氣管擴張劑
  • 皮質類固醇
  • 氧氣療法
  • 其他

第7章 市場區隔：依給藥途徑

  • 腸外
  • 吸入
  • 口服

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 專科診所
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • AstraZeneca PLC
    • CH Boehringer Sohn AG & Ko. KG
    • CSL Limited
    • GlaxoSmithKline Plc
    • Grifols SA
    • Kamada Ltd.
    • LFB Biomedicaments SA
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112026A2467

The global alpha 1 antitrypsin deficiency treatment market size reached USD 2.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 4.4 Billion by 2034, exhibiting a growth rate (CAGR) of 7.14% during 2026-2034.

Alpha-1 antitrypsin (AAT) deficiency refers to a genetic disorder due to which the body does not produce sufficient AAT protein. AAT protein is essential for protecting the lungs and liver from the adverse effects of other proteins in the body. Patients with severe AAT deficiency may develop liver cirrhosis, chronic obstructive pulmonary diseases (COPD) and emphysema diseases. It can be diagnosed through a genetic or a blood test. Some of the treatment methods include augmentation therapy, pulmonary rehabilitation and oxygen therapy that use medicines, such as bronchodilators and corticosteroids, which can be injected intravenously or inhaled.

The increasing prevalence of respiratory disorders is one of the key factors driving the growth of the market. Furthermore, widespread adoption of augmentation therapy is providing a thrust to the market growth. This therapy involves extracting AAT protein from a healthy donor's blood plasma for increasing AAT levels in the respiratory tract of patients. In line with this, this treatment also delays the progression of emphysema, minimizes the frequency of exacerbations and improves recovery speed, which, in turn, is contributing to its increasing preference among both the patients and healthcare providers. Additionally, various technological advancements in the diagnostic methods and the development of innovative processes for the production and purification of AAT are acting as other growth-inducing factors. They have improved quality and are free from contaminants, such as viruses and bacteria. Other factors, including extensive research and development (R&D) activities, along with improvements in medical infrastructure, are anticipated to drive the market further.

KEY MARKET SEGMENTATION:

Breakup by Treatment Type :

  • Augmentation Therapy
  • Bronchodilators
  • Corticosteroids
  • Oxygen Therapy
  • Others

Breakup by Route of Administration:

  • Parenteral
  • Inhalation
  • Oral

Breakup by End User:

  • Hospitals
  • Specialty Clinics
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

COMPETITIVE LANDSCAPE:

The competitive landscape of the industry has also been examined with some of the key players being AstraZeneca PLC, C.H. Boehringer Sohn AG & Ko. KG, CSL Limited, GlaxoSmithKline Plc, Grifols S.A., Kamada Ltd., LFB Biomedicaments S.A., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

1. How big is the alpha 1 antitrypsin deficiency treatment market?

2. What is the future outlook of alpha 1 antitrypsin deficiency treatment market?

3. What are the key factors driving the alpha 1 antitrypsin deficiency treatment market?

4. Which region accounts for the largest alpha 1 antitrypsin deficiency treatment market share?

5. Which are the leading companies in the global alpha 1 antitrypsin deficiency treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Alpha 1 Antitrypsin Deficiency Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Augmentation Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bronchodilators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Corticosteroids
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Oxygen Therapy
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Parenteral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Inhalation
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oral
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca PLC
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 C.H. Boehringer Sohn AG & Ko. KG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 CSL Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 GlaxoSmithKline Plc
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Grifols S.A.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Kamada Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 LFB Biomedicaments S.A.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Takeda Pharmaceutical Company Limited
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio

List of Figures

  • Figure 1: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Treatment Type (in %), 2025
  • Figure 5: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Route of Administration (in %), 2025
  • Figure 6: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Alpha 1 Antitrypsin Deficiency Treatment (Augmentation Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Alpha 1 Antitrypsin Deficiency Treatment (Augmentation Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Alpha 1 Antitrypsin Deficiency Treatment (Bronchodilators) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Alpha 1 Antitrypsin Deficiency Treatment (Bronchodilators) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Alpha 1 Antitrypsin Deficiency Treatment (Corticosteroids) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Alpha 1 Antitrypsin Deficiency Treatment (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oxygen Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oxygen Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Alpha 1 Antitrypsin Deficiency Treatment (Parenteral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Alpha 1 Antitrypsin Deficiency Treatment (Parenteral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Alpha 1 Antitrypsin Deficiency Treatment (Inhalation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Alpha 1 Antitrypsin Deficiency Treatment (Inhalation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Alpha 1 Antitrypsin Deficiency Treatment (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Alpha 1 Antitrypsin Deficiency Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Alpha 1 Antitrypsin Deficiency Treatment (Specialty Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Alpha 1 Antitrypsin Deficiency Treatment (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: North America: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: North America: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: United States: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: United States: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Canada: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Canada: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Asia Pacific: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Asia Pacific: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: China: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: China: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Japan: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Japan: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: India: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: India: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: South Korea: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: South Korea: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Australia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Australia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Indonesia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Indonesia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Europe: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Europe: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Germany: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Germany: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: France: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: France: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: United Kingdom: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: United Kingdom: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Italy: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Italy: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Spain: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Spain: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Russia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Russia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Latin America: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Latin America: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Brazil: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Brazil: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Mexico: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Mexico: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Middle East and Africa: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Middle East and Africa: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: SWOT Analysis
  • Figure 79: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: Value Chain Analysis
  • Figure 80: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 3: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 4: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Competitive Structure
  • Table 7: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Key Players